Podcasts about ccr

It's hard to believe that CCR has been on the air for ten years and produced more than 200 episodes, so Alex sits down and thinks back on how CCR got started and some of the favourite episodes from the past. Including the mysterious Episode 0 and the far better Episode 1, which was recorded. Some good interviews, some of the more nerdy episodes, and the ones that certainly got CCR a tonne of attention. Plus a little bit of encouragement for those thinking of starting up a blog, podcast, or YouTube channel. CCR is ten years old this year, and to celebrate, we're hosting a Photowalk & Brewery Tour on 12 July starting at 11 am from the Great Lakes Brewpub at 11 Lower Jarvis in Toronto, Ontario. You can find more details on the event signup page on: Photowalk.me!

Kom med en tur tilbage til forgangne somre, og hør eller genhør numre som vi har gået og nynnet i sommervarmen, lyttet til i radioen, numre der har gjort os i godt humør. Du kommer i selskab med en række sange fra 60'erne og 70'erne, lyt med til: CCR, Seals & Croft, Doobie Brothers, Supremes, … Læs videre "Sommerhits 2"

După o lună de negocieri politice pe viitoarea echipă a Guvernului și pe viitoarele măsuri de redresare macro-economică, pe coșul de la Palatul Cotroceni - sau Victoria - a ieșit, în sfârșit, fum. Pentru mulți alb, pentru noi mai degrabă maro.Dincolo de speranțele puse în persoana premierului Bolojan, o parte importantă din cabinet este cel puțin discutabilă.Am discutat și noi despre oamenii-problemă împinși de noua coaliție de guvernare la masa Guvernului, dar și prin tot felul de alte funcții. Am început cu ministrul Justiției, despre ale cărui fapte de arme din vremea când era avocat noi considerăm că nu-l recomandă nicidecum pentru portofoliul din guvernul asumat reformist.Am cotinuat cu alți și alți inși de genul „inexplicabil”: Cătălin Predoiu, Florin Barbu, Rogobete sau „Elon” Anastasiu.Dincolo de echipa guvernamentală, însă, lucrurile par să stea și mai rău: Lia Savonea conduce puterea judecătorească, iar puterea judecătorească pare să n-aibă nimic împotrivă, iar la CCR ajunge, cel mai probabil, un fel aparte de slugoi perpetuu al liderilor PSD, Mihai Busuioc, cu votul USR.Deșertăciune, ați spune, și noi nu ne-am opune absolut deloc, ba chiar ne-am alătura corului.Una peste alta, nu știu voi, dar noi am conchis că ne-am cam pierdut răbdarea, precum și că momentul victoriei reformistului pro-european Nicușor Dan în turul II, cu tot cu momentum-ul creat de el, s-a cam dus.Ce-o veni? Nu știm, dar vă promitem că rămânem aici să constatăm și să judecăm. Săptămâna viitoare, însă, nu joi, cum v-am obișnuit, ci marți. Mulțumim! Pe curând!-----------Fiind un produs editorial al unor organizații de presă independentă - Dela0 și Centrul de Investigații Media (CIM) - Judecata de Acum se bazează pe suportul financiar al publicului. Ne puteți sprijini cu un abonament lunar prin patreon: www.patreon.com/judecatadeacum. Mulțumim!

Taxă pe gândire. Când bursa devine vis și cartea - lux (SpotMedia) - Statul închide robinetul de mercenari: Guvernul vrea să oprească migrarea cadrelor din Poliție și Armată către armate private, sub pedeapsa închisorii (PressOne) - Ar trebui ca România să ofere avioane F16 Ucrainei? Expert: „Summitul NATO stimulează statele europene să doneze Kievului vechituri” (Adevărul) Guvernul se pregătește să taie sporurile pentru bugetari de la 1 iulie. Ce ia din sporuri va da la consumatorii vulnerabili de energie (HotNews) Guvernul caută soluții pentru a face economii la buget începând chiar cu 1 iulie, fiind luată în calcul inclusiv reducerea sau eliminarea unor sporuri acordate bugetarilor, au declarat, pentru HotNews, surse guvernamentale. Graba noului Executiv este dată de urgența adoptării unor măsuri de protejare, de la 1 iulie, a consumatorilor vulnerabili de energie, pentru care sunt necesare sume mari de la bugetul statului. Cele două proiecte de OUG anunțate de HotNews.ro au ajuns spre avizare la Consiliul Economic și Social (CES). Deși este doar consultativ, avizul CES este obligatoriu înainte de adoptarea oricărui act normativ. 12,4 miliarde de lei s-au dat pe sporuri anul trecut. România are peste 3,7 milioane de consumatori vulnerabili. Mecanismul de sprijin pentru consumatorii vulnerabili, după ridicarea plafonării prețurilor la energie de la 1 iulie 2025, prevede un sprijin lunar în valoare de 50 de lei pentru o perioadă de 9 luni, de la 1 iulie 2025 până la 31 martie 2026. Sunt 2 categorii de beneficiari: persoană singură cu un venit net lunar de maxim 1940 lei familii cu un venit net lunar/membru de maxim 1784 de lei. Taxă pe gândire. Când bursa devine vis și cartea - lux (SpotMedia) Analfabetismul funcțional se apropie de 50%, iar ministrul-psiholog al Educaţiei a decis că bursele sunt prea scumpe. Nu sunt prea scumpe pensiile speciale. De ele nu te poţi atinge că… CCR. Nu sunt prea scumpe subvențiile de zeci de milioane de euro pentru partide. Aici sunt banii de propagandă, cum să-i tai? Nu sunt prea scumpe salariile uriașe din autorităţile şi companiile de stat (unele falimentare), unde se premiază incompetența și pilele. Acum câteva luni acelaşi ministru spunea pe bună dreptate că analfabetismul funcțional e chestiune de securitate naţională. Au trecut alegerile, ne-a lovit brusc conştiinţa bugetului şi deodată nu mai e nicio problemă. Ba chiar se mai poate tăia niţel din banii pentru şcoală. Aşa că acum ministrul David le spune cinic elevilor şi studenților să accepte mai puțini bani pentru burse. De ce? Pentru că, „în situații de criză, lucrurile sunt complicate. Și să vrei, n-ai de unde”. Şi asta în condițiile în care România oricum cheltuie printre cei mai puțini bani din UE pe educație, raportat la PIB. Ne aflăm la același nivel cu Tanzania, după state precum Zambia, Anguilla, Palau, Benin și Panama. România e țara în care educația moare cu zile și e ucisă de cei care ar trebui s-o salveze, scrie Bogdana Boga, redactor șef SpotMedia. Statul închide robinetul de mercenari: Guvernul vrea să oprească migrarea cadrelor din Poliție și Armată către armate private, sub pedeapsa închisorii (PressOne) Ministerul Afacerilor Interne a depus pentru dezbatere publică un proiect de ordonanță de urgență prin care se dorește corectarea portițelor legislative care au permis angajaților din sistemul național de apărare, ordine publică și securitate națională să furnizeze cadre pentru armata privată a lui Horațiu Potra. Corecția se va aplica mai multor legi care reglementează statutul angajaților din sistemul de securitate și urmărește interzicerea în mod expres a prestării de munci pentru companii militare private, chiar și după trecerea în rezervă și sub amenințarea pedepsei cu închisoarea de la 2-7 ani. Hemoragia de personal de specialitate antrenat pentru condiții de luptă pe banii statului român, către compania militară privată deținută de mercenarul Horațiu Potra a ridicat grave probleme de securitate în ultimii ani. PressOne a arătat în mai multe articole că Armata Română, Poliția, Jandarmeria și alte instituții de forță din zona de ordine publică și securitate au furnizat începând cu 2022 sute de combatanți în compania lui Potra care au luptat în Republica Democrată Congo. Ar trebui ca România să ofere avioane F16 Ucrainei? Expert: „Summitul NATO stimulează statele europene să doneze Kievului vechituri” (Adevărul) La summitul NATO de la Haga s-a stabilit că în procentul de 5% din PIB pentru apărare vor intra și ajutoarele militare pentru Ucraina. Ce va însemna acest lucru pentru dotarea ucrainenilor și ce ar putea România să doneze/să achiziționeze a explicat experta în securitate europeană Iulia Joja. „Dacă e să analizăm cinic, acest articol presupune că statele europene care încă nu s-au debarasat de toate vechiturile să le doneze Ucrainei și să adauge la bugetul militar valoarea aproximativă a acelor echipamente”, explică Joja. Experta analizează și în ce măsură pentru România este o oportunitate de a „scăpa”, de  avioanele F 16 pe care le deține și de a achiziționa mult mai performantele F-35. Pe larg în ziarul Adevărul.

It's HardLore Summer and the sun is blazing, a little too much. It's too hot and it sucks.But you know what doesn't suck? These 20 records we're about to talk about.HAGS,Love, HardLore xoxoOFFICIAL COMPANION PLAYLIST: Spotify - https://open.spotify.com/playlist/3Vsxrp3imUDVD8wTHH88Ix?si=511319323b864b26 Apple Music - https://music.apple.com/us/playlist/hardlores-top-20-summer-albums/pl.u-4JommaDuJ03DPrAEdited by Steven Grise (@iamoneonenineseven) • Title sequence by Nicholas Marzluf (@marzluf)HardLore: A Knotfest SeriesJoin the HARDLORE PATREON to watch every single weekly episode early and ad-free, alongside exclusive monthly episodes: https://patreon.com/hardlorepodJoin the HARDLORE DISCORD: https://discord.gg/jA9rppggefCool links:HardLore Official Website/HardLore Records store: https://hardlorepod.comTry AG1 at DrinkAG1.com/HARDLORE to receive a free 1-year supply of vitamin D and 5 travel packs of AG1.Get 15% off MADD VINTAGE with code HARDLORE15! https://maddvintage.com/Get 20% OFF @manscaped + Free Shipping with promo code HARDLORE at MANSCAPED.com! #ad #manscapedpod FOLLOW HARDLORE:INSTAGRAM | https://www.instagram.com/hardlorepod/TWITTER | https://twitter.com/hardlorepodSPOTIFY | https://spoti.fi/3J1GIrpAPPLE | https://apple.co/3IKBss2 FOLLOW COLIN:INSTAGRAM | https://www.instagram.com/colinyovng/TWITTER | https://www.twitter.com/ColinYovng FOLLOW BO:INSTAGRAM | https://www.instagram.com/bosxe/TWITTER | https://www.twitter.com/bosxe#HARDLORE #HARDCORE 00:00:00 - Start00:00:41 - Introduction00:02:03 - New Found Glory - Sticks and Stones00:03:38 - Diamond - Don't Lose Your Cool00:05:54 - Cro-Mags - Best Wishes00:08:22 - Suicidal Tendencies - Self Titled00:10:21 - Warpaint - Self Titled00:11:58 - A$AP Ferg - Trap Lord00:14:32 - AFI - Shut Your Mouth and Open Your Eyes00:17:05 - The Mighty Mighty Bosstones - Let's Face It00:19:07 - Down - NOLA00:21:03 - Faith No More - The Real Thing00:23:27 - Fall Out Boy - From Under The Cork Tree00:25:39 - Rancid - ...Out Come The Wolves00:27:22 - Godflesh - Streetcleaner00:29:30 - Pardon This Interruption...00:32:36 - Bad Religion - No Control00:34:37 - Creedence Clearwater Revival - Best of00:36:52 - Lana Del Rey - Born To Die (Paradise Edition)00:39:31 - Saves The Day - Through Being Cool00:41:36 - Cave In - Antenna00:43:38 - Bo's #100:45:34 - Colin's #100:48:29 - Honorable Mentions

In this episode, CCR debates the issues!Follow:Zac Loughman @https://www.instagram.com/dr_crawdad/On FB https://www.facebook.com/profile.php?id=100011423011423Clint Bartley @IG: MetazoticsLLC FB: MetazoticsWebsite: metazotics.comPatreon:https://www.patreon.com/c/ColubridandColubroidRadio/Discord:http://discord.gg/ccradioExo-terrahttps://exo-terra.comhttps://linktr.ee/exoterrausaMPR NetworkFB: https://www.facebook.com/MoreliaPythonRadioIG: https://www.instagram.com/mpr_network/YouTube: https://www.youtube.com/channel/UCtrEaKcyN8KvC3pqaiYc0RQSwag store: https://teespring.com/stores/mprnetwork ★ Support this podcast on Patreon ★

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Vladimir Putin nu doar că nu a renunțat la a viza România, dar aceasta a devenit țintă directă, după ce Kremlinul a înțeles care este slăbiciunea de fond pe care o poate alimenta până la haos. Și nu poate fi o coincidență noua aliniere a lui George Simion la retorica rusească, scrie Magda Grădinaru în spotmedia.ro ”După scrutinul prezidențial care i-a alunecat Rusiei printre degete, manipularea și dezinformarea s-au industrializat, în sensul în care, pe de o parte, sunt executate mult mai profesionist și mai programatic și, pe de altă parte, sunt asumate fățiș de către Rusia și agenții ei. Trei mari narațiuni se desprind aici: Intrarea României în război și mobilizarea generală; Imixtiunea reciprocă în treburile interne ale celuilalt stat, a României și Republicii Moldova; Atacul asupra identității culturale și religioase a României care se opune primelor două narațiuni. O notă comună extrem de importantă este aceea că aceste narațiuni sunt declinate și rostogolite mai mult în grupurile și rețelele de români din diaspora, ceea ce arată strategia de consolidare a ceea ce istoricul Cosmin Popa numește „anti-România” și care a devenit una dintre direcțiile majore ale intervenției rusești în România”. Adevărata șmecherie a deciziei CCR care secretizeză averile demnitarilor și funcționarilor publici. Unde sunt adevărații bani (Adevărul) ”Motivarea deciziei CCR care secretizează averile demnitarilor și pe cele ale funcționarilor publici și rudelor acestora face o oarecare lumină în scandalul creat după pronunțarea deciziei. Specialiștii consultați de „Adevărul” susțin că judecătorii constituționali au dat o direcție în ceea ce privește viitoarea legislație: persoanele alese sau numite politic publică declarațiile de avere, în timp ce funcționarii, nu”. Fostul ministru de finanțe al PSD, membru în echipa de negociere a bugetului și care propune taxa de solidaritate, a venit la discuții într-un Mercedes de 100.000 de euro care nu apare în declarația de avere (Snoop) ”Fostul ministru de finanțe al PSD, membru în echipa de negociere a bugetului și care propune taxa de solidaritate, a venit la discuții într-un Mercedes de 100.000 de euro care nu apare în declarația de avere”, scrie siteul de investigație Snoop. „Mercedesul e închiriat de la compania unui prieten care nu are legături cu statul și nu e o mașină de lux”, a răspuns deputatul PSD Adrian Câciu, întrebat de siteul de investigații Snoop despre mașina Mercedes GLE 450, care costă cel puțin 100.000 de euro și nu apare în declarația sa de avere. Compania se numește Pandorama Elite SRL, a descoperit Snoop și este în proprietatea firmei fostei soții, care figura în 2024 ca angajată la Autoritatea de Supraveghere Financiară (ASF). Drumul spre dezastru de la Salina Praid: Licitații, încredințări directe și ajutoare de peste jumătate de miliard de lei. Oficialii aveau date despre pericol (Libertatea) ”Mai mult, lipsesc banii din întreaga poveste. Cu o regulă nescrisă, o licitație din aprilie a fost câștigată de o firmă care a prezentat un proiect de drum, în loc de o lucrare hidrotehnică. Câștigătorul a ghicit cumva bugetul ascuns. O altă firmă mică a obținut un contract de 30 de milioane de lei prin încredințare directă, iar acum se discută de lucrări care ajung la aproape 90 de milioane de lei”.

In this episode, join us as we discuss CCR's first herping trip!Follow:Zac Loughman @https://www.instagram.com/dr_crawdad/On FB https://www.facebook.com/profile.php?id=100011423011423Clint Bartley @IG: MetazoticsLLC FB: MetazoticsWebsite: metazotics.comPatreon:https://www.patreon.com/c/ColubridandColubroidRadio/Discord:http://discord.gg/ccradioExo-terrahttps://exo-terra.comhttps://linktr.ee/exoterrausaMPR NetworkFB: https://www.facebook.com/MoreliaPythonRadioIG: https://www.instagram.com/mpr_network/YouTube: https://www.youtube.com/channel/UCtrEaKcyN8KvC3pqaiYc0RQSwag store: https://teespring.com/stores/mprnetwork ★ Support this podcast on Patreon ★

They say that everything is bigger in Texas, and that certainly includes the personalities of the film photographers! Join Alex as he sits down with Nick LoPresti, if you haven't seen his work he certainly has a certain flare for humour, big jokes a bit of self-deprecation and a flare for not taking himself seriously. And you know, it's a refreshing take on a hobby that often takes itself way too seriously. I mean, we here at CCR can often lean into the serious side of things, but we also don't take ourselves too seriously. To find more of Nick's Work, check him out in the following places online! Web: www.madebylopro.com Instagram: www.instagram.com/loprestiproductions/ YouTube: www.youtube.com/@nicklopro CCR is ten years old this year, and to celebrate, we're hosting a Photowalk in Brewery Tour on 12 July starting at 11 am from the Great Lakes Brewpub at 11 Lower Jarvis in Toronto, Ontario. You can find more details on the event signup page on www.photowalk.me!

This week on RITY... The mini theme is A Game Of Monopoly... Plus, John Fogerty gives us a new take on one of his CCR tunes... Jim Peterik talks about the inspiration behind the song, "Vehicle"... The story of how The Beatles "officially" disbanded at what some refer to as the "Happiest Place On Earth"... Deep cuts from R.L. Burnside, John Entwistle, Fenton Robinson, The Knack, and much more! For more info on the show, visit reelinwithryan.com

Enjoying the Ride: On TourThe Deadcast season finale hits shows at 3 legendary venues, exploring Dick Latvala's transformative experience at Red Rocks ‘79, Hollie Rose's tour journal, the wonders of the Alpine Valley parking lot, & when Shakedown Street got its name.Guests: David Lemieux, Jay Kerley, Hollie Rose, Rebecca Adams, Bill Lemke, Phil Garfinkel, Jim Jonze, Tom Ryan, Art Moss, Lisa Hitchcock, David Van Divier, Scott Bauer, Julie Dock, Mobile SteeleSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

(00:00-6:31) The Gibb brothers. DJ Pattycakes has some data points on NBA viewership in the YouTube Chat. Regular season viewership down across the board.(6:39-10:15) Any time you can play some CCR, it's worth it. The Athletic looking at teams that could shape the MLB trade deadline. Ryan Helsley. Have faith in John King.(10:25-18:26) E-Mail of the DaySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today, it's Sabrina Carpenter: Is her new video a Madonna reference? Kesha enjoys a banana split on stage… sort of. John Fogerty is re-recording “John's Versions” of classic CCR hits. Roommates can drive you crazy, but you can't strangle people. Game time: When did random stuff happen?

Are you ever going to text me?This episode includes "Cousin Oliver,” so it may be the beginning of the end for CCR.Jason, Jim, and Joseph create a list of the best TV Child Actors.Pat Johnson's squirrel graveyard.The question that triggers Joseph the most is, "Did I do that?”Jim serenades everyone with the theme song to "Eight is Enough.”Big toilet and little toilet.Franklin Delano BluthLittle Opie Cunningham.Joseph talks about a couple of Eddie Haskell's his daughter dated.Jason rejects Jim and Joseph's half-hearted apology for last week's episode.Which child actor stole the show from J.J.?Was there child abuse in the Cleaver's household?

Watch This Episode On YouTubeWith the baritones of Bono and U2 as the soundtrack, the globe-trotting world of Mary Robinson requires an epic film to depict her life, and thankfully, they found the director that can deliver just that in Irish filmmaker Aoife Kelleher.Aoife gave us the brilliant film MRS ROBINSON (2024), still on its festival run. MRS ROBINSON tells the inspirational life story of change-maker Mary Robinson: Ireland's first female President, a pioneering UN High Commissioner for Human Rights, and the successor of Nelson Mandela as Chair of The Elders.And if all that wasn't enough, check out her film, TESTIMONY (2025), also on the festival circuit. Not sure when Aoife has time to sleep but she found time to talk with me for the podcast, and I'm delighted to share that conversation with you.In this episode, Aoife and I discuss:her biographical statement that she seeks in her work to "tell hidden truths about Ireland and Irishness" -- what does that mean? what is an Irish film?;how did she get involved in filmmaking? "my parents were primary school principals and my dad was a politician so it was like, there were a lot of debates around these kind of themes at the dinner table";her switch from law to filmmaking -- "I'd had this work experience in a legal firm that had put me off the idea of pursuing law";what did she learn from her first documentary ONE MILLION DUBLINERS (2014) that she takes away for her current film?how did she get the opportunity to make MRS ROBINSON (2024), even with pitching against many other companies -- "you really can't stress [enough] how large Mary Robinson looms in Irish society";how she made it clear they weren't creating a puff piece documentary -- "from the earliest points in the pitching process, we made it clear that we would not be doing that, and that was what she wanted, too";how she was able to license U2 and other prominent musicians as part of this film (they were going to play "Fortunate Son" by CCR in a Vietnam scene...I think it worked out better with Bono!);the climate activism portion of the film and how it resonates now versus 30 years ago;how has documentary changed in the last ten years?;what's next for her? TESTIMONY (2025) is also on the festival circuit, which means she has TWO feature films on the circuit right nowAoife's Indie Film Highlight: BLUE ROAD: THE EDNA O'BRIEN STORY (2024) dir. by Sinead O'Shea; A WANT IN HER (2024) dir. by Myrid CartenLinks:MRS ROBINSON (2024) WebsiteFollow Screen Ireland on Instagram For More Info On Irish FilmmakersWatch This Episode On YouTubeSupport this podcast at — https://redcircle.com/first-time-go/exclusive-content

Livvy Dunne publicly wants her privacy, Corey Feldman strains to explain, Eli Zaret in studio, Silk Road's Ross Ulbricht's crypto speech, besties Tom Cruise & David Beckham ballwash each other, and a deep dive into the Sloopy Girl podcast. Is Jim Bentley a David Hall Financial bobblehead winner or loser? We discuss children allowances, and learn Eli was counting his coins with an abacus. Eli Zaret joins the program to discuss a little John Fogerty and CCR, the red-hot Detroit Tigers, another Honus Wagner baseball card record sale, the NBA Finals, Zion Williamson rape accusations, the Stanley Cup Finals, Travis Hunter duel-eligibility, NBA mock drafts, a male winning women's sports again… and again, WNBA hogwash and more. Corey Feldman did an impromptu interview with TMZ and is straining to do some explaining about his What's Eating Gilbert Grape and Titanic claims. This kid gets a bunch of money for having a job on graduation day. Emmanuel Macron gets the lip reading treatment. Brigitte Macron is not a dude, stop calling the Bonerline. Reminder that Tawana Brawley is a liar. The Imagine Dragons love Palestine. Convicted and pardoned Silk Road founder, Ross Ulbricht is back and doing speeches. He also received 300 Bitcoin ($31M). There was a terrorist attack in Boulder, Colorado. Greta Thunberg forgot about the climate. Goes full Hamas. Livvy Dunne claims she is being stalked and she's super bummed about it. Matthew Stafford sits in first class while his family sat in coach. Marc had a dance party this weekend. Lisa Leonard Dalton (Sloopy Girl) has a hell of a YouTube channel with crazy in-depth reporting. Farve Girl Jenn Sterger won't go away and is doing stand up comedy. Brooklyn Beckham and his wife are causing strife in the family. Great fathers Tom Cruise and David Beckham are besties. They ball washed each other during the UEFA Champion's League final. If you'd like to help support the show… consider subscribing to our YouTube Channel, Facebook, Instagram and Twitter (Drew Lane, Marc Fellhauer, Trudi Daniels, Jim Bentley and BranDon).

Van Morrison actuará esta semana en el marco de la novena edición de las Noches del Botánico, ciclo de conciertos que desde El Real Jardín Botánico Alfonso XIII de Madrid ofrece un amplio surtido de actuaciones para todos los gustos. John Fogerty anuncia nueva compilación en donde ha regrabado 20 canciones de Creedence Clearwater Revival. Y despedimos a James Wales, vocalista de la psicotrópica banda californiana de los 60 The Electric Prunes.Playlist;(sintonía) VAN MORRISON “Breadwinner” (Beyond Words: Instrumental, 2023)VAN MORRISON “Days like this” (Days like this, 1995)VAN MORRISON “Down to joy” (Remembering now)VAN MORRISON “Only a song” (Latest record project; volume 1, 2021)VIAGRA BOYS “Man made of meat” (Viagr aboys)SANTANA “Black magic woman/Gypsy Queen” (Abraxas, 1970)JOHN FOGERTY “Up around the bend” (Legacy; the CCR years)JOHN FOGERTY “Porterville” (Legacy; the CCR years)VIV and THE SECT “No tengo miedo” (II)THE ELECTRIC PRUNES “I has too much to dream last night” (ST, 1967)THE ELECTRIC PRUNES “Train to tomorrow” (ST, 1967)ROBERT FORSTER “Good to cry” (Strawberries)TY SEGALL “Skirts of heaven” (Possession)THE BEAT “All over the world” (To beat or not to beat, 1983)Escuchar audio

PSD, în căutarea doctrinei pierdute. Cum poate partidul să recâștige încrederea electoratului ANALIZĂ (Adevărul) - INTERVIU Important economist, autor a 50 de cărți: „Un dezastru pentru România. Adică lucrez și 65% dau la stat?” / Dă un exemplu de companie de stat „pe care politicienii au pus-o pe butuci” (HotNews) - România, pământ chinezesc. Branduri românești sunt aplicate pe produse realizate în China și apoi vândute în țara noastră. Expert: „Este un vid legislativ” (Libertatea) Elefantul din odaia nașterii guvernului și fereastra de timp care se închide (SpotMedia)De aproape o lună România are premier și guvern interimar cu puteri limitate. Nu va putea trimite pe 4 iunie la Bruxelles un plan fiscal adoptat de reducere a deficitului bugetar la 7%, o reformă fără de care urmează blocarea fondurilor europene.E posibil să fi obținut de la Comisia Europeană o mică amânare, până la final de iunie, pentru adoptarea planului prin OUG, altă soluție nu prea există, de către un guvern cu puteri depline.Ca să ne încadrăm măcar în această amânare, săptămâna aceasta ar trebui să avem cel puțin numele premierului și formarea guvernului să intre în linie dreaptă.Există un singur nume politic credibil, de la distanță, pentru cetățeni. Ilie Bolojan. Dar cel mai mare partid, indispensabil guvernării, este PSD. De el depinde însăși existența guvernului și în mod normal el ar putea pretinde legitim funcția.PSD nu o vrea în mod special, dar nici nu o poate da degeaba. Deci cere compensații. Și pe masă e zestre mare, de la șefia SRI, pe care președintele doar o propune, majoritatea o decide în Parlament, șefia Camerei Deputaților, a Senatului, dacă dl Bolojan devine premier, doua poziții de judecători CCR, ministerele cheie, șefiile radio și TV publice, Avocatul Poporului etc.Și, sigur, mai există o întrebare cheie. Poate Ilie Bolojan să aibă încredere în PSD, în solidaritatea acestuia la greu, chiar dacă obține un acord acoperitor al coaliției?Pe de o parte, PSD nu are decât o conducere provizorie până la congresul din august. Acum va semna Sorin Grindeanu, dar asta nu înseamnă că viitorul președinte va rămâne de acord cu înțelegerea și că o nouă formulă de conducere nu va încerca să o remodeleze sub presiunea răsturnării guvernului.Sunt multe întrebări sensibile în jurul cărora se învârt discuțiile acestor zile, dar ar fi  grav să mai treacă o săptămână cu tot felul de comisii și tatonări, fără desemnarea unui premier, comentează pe pagina SpotMedia jurnalista Ioana Ene Dogioiu.PSD, în căutarea doctrinei pierdute. Cum poate partidul să recâștige încrederea electoratului ANALIZĂ (Adevărul)Finalul ciclului electoral deschide în PSD o perioadă cu mize ce depășesc simpla schimbare de lideri. În toamnă, formațiunea politică va organiza un Congres pentru alegerea noii conduceri și redefinirea liniei ideologice. Cei care solicită schimbarea doctrinei au spus că Partidul Social Democrat trebuie să devină un partid conservator. Astfel, la următorul Congres al PSD partidul ar părăsi familia social-democrată europeană și ar putea să își schimbe și numele.În prezent, statulul PSD menționează că „Partidul Social Democrat este un partid de stânga modern şi progresist, un partid naţional cu vocaţie europeană, membru al Partidului Socialiştilor Europeni şi al Internaţionalei Socialiste, continuatorul tradiţiei social-democraţiei româneşti” și „promovează doctrina social-democrată”.Politologul Cristian Pârvulescu explică faptul că „stânga se centrează pe egalitate. Și la marile subiecte care sunt cruciale pentru egalitate, PSD este pe poziție ultraconservatoare cvasifascistă. De exemplu, problema căsătoriei între persoanele de același sex sau a parteneriatului civil. Problema avortului. (...) Problema migrației. Sunt foarte multe probleme pe care le abordează din perspectivă de dreapta. (...) în Europa centrală și de est nu s-au putut construi partidele de stânga, pentru că au fost decredibilizate de comuniști și pentru că nu prea a existat susținere”.Practic, PSD este un partid post-comunist dezideologizat, un partid care încearcă să ia voturi de peste tot, pentru care ideologia nu are nicio importanță, completează expertul pentru ziarul Adevărul.INTERVIU Important economist, autor a 50 de cărți: „Un dezastru pentru România. Adică lucrez și 65% dau la stat?” / Dă un exemplu de companie de stat „pe care politicienii au pus-o pe butuci” (HotNews)Directorul Institutului de Prognoză Economică din cadrul Academiei Române, Lucian Albu, reputat economist de dreapta și profesor, a discutat pentru publicul HotNews despre măsurile necesare României în dezbaterea echilibrării bugetului. Albu a atras atenția că una dintre cele vehiculate măsuri poate avea cele mai nefaste efecte pentru populație: impozitarea progresivă. „Cum am mai stimula forța de muncă să mai muncească?”, spune el. Economistul consideră că pe termen scurt creșterea TVA pentru celelate categorii care nu sunt în prezent la cota de 19% poate să fie o sursă „foarte sigură de a crește gradul de colectare și de a mai reduce din deficit”.România, pământ chinezesc. Branduri românești sunt aplicate pe produse realizate în China și apoi vândute în țara noastră. Expert: „Este un vid legislativ” (Libertatea)Tot mai multe companii autohtone comercializează în România produse cu propriile branduri și logouri, dar, de fapt, acestea sunt realizate în China. Acest fenomen se observă în special în industria auto și cea de electronice, dar este valabil și în altele, precum mobilă sau textile.Aceste produse sunt mai scumpe decât se vând în statul asiatic, câteodată costă chiar dublu sau triplu, sunt dar mai ieftine decât modelele europene sau americane similare comercializate în țara noastră. Libertatea vă prezintă cele mai întâlnite cazuri.Dacia Spring este, de fapt, un Dongfeng.Modelul electric al producătorului auto nu are nimic de-a face cu fabricile de la Mioveni. Acesta este produs în China de către un alt partener de afaceri al Renault, respectiv producătorul de stat Dongfeng. Însă în timp ce modelul chinez pornește cu un preț de la 5.500 de dolari pe Alibaba, echivalentul a 4.850 de euro, în România, grupul francez a trecut un preț de pornire de la 16.900 de euro în cea mai puțin dotată versiune, conform site-ului Dacia. Versiunea cea mai scumpă are un preț de listă de 19.900 de euro. Prețul prin programul Rabla pleacă de la 11.400 de euro.Sorin Mierlea, președinele asociației Infocons, care se ocupă cu protecția consumatorilor, spune că nu există legislație care să definească foarte clar ce înseamnă produs românesc.

John Fogerty just turned 80 and he has rerecorded all of his CCR hits! Taking a page from Taylor Swift, Fogerty regained control of his music & has rerecorded those great CCR tracks with a new band that includes at least 2 of his kids!

CCR has...thoughts about the Final Fantasy set. Thanks as always to Wave Sunray for our music! If you'd like to support the podcast, check out our patreon at patreon.com/mtggrindcast. Subscribers get swag and bonus content! And whether you subscribe or not, you're invited to join our discord, where we're building a community of friendly people all looking to improve at the game we love. Check it out here: https://discord.gg/Uq8x2RHYRU

As convidadas do programa Pânico dessa quarta-feira (28) são Madeleine Lacsko e Dani Freixo.Madeleine LacskoMadeleine Lacsko é jornalista, palestrante e consultora de risco reputacional. Atua como colunista em O Antagonista, Gazeta do Povo e UOL News. Apresenta o podcast PodFalar, sobre liberdade de expressão. É sócia da Gonew, edTech de lifelong learning.Faz parte do conselho do Instituto Monitor da Democracia e está fundando o Instituto Direito de Fala, pela Liberdade de Expressão. É autora do livro Cancelando o Cancelamento - como o identitarismo da militância tabajara ameaça a democracia.Trabalhou nas Rádios Trianon e Jovem Pan. Foi consultora do Unicef na erradicação da pólio em Angola, assessora do STF e da Alesp, diretora de comunicação da Change.org e assessora de marketing da CCR.Redes Sociais: Instagram: https://www.instagram.com/madeleinelacsko/X: ⁠https://x.com/madeleinelacskoYouTube: ⁠https://www.youtube.com/@podfalarmadeleinelacskoDani FreixoDaniella Freixo é psicóloga infantil com especialização em Psicologia Analítica de Jung e formação pela DEP em Transpessoal. Busca em seus conteúdos ensinar como é possível educar crianças com direção, acolhimento, responsabilidade, respeito e autonomia.Redes Sociais:Instagram: ⁠https://www.instagram.com/daniellafreixo/

“Would you rather have your nuts run over than listen to post-‘Toys in the Attic' Aerosmith?”Welcome to a riotous and unfiltered episode of The Ben and Skin Show on 97.1 The Eagle, where Ben Rogers, Jeff “Skin” Wade, Kevin “KT” Turner, and Krystina Ray dive headfirst into the ultimate rock ‘n' roll debate: Who's the greatest band for every letter of the alphabet?Fueled by Loudwire's “Rock and Roll Alphabet” list, this episode is a chaotic blend of music nerdery, generational hot takes, and laugh-out-loud moments that will have you yelling at your speakers—and maybe even questioning your own taste in music.

It's hard to believe that 2025 marks several significant anniversaries. First off, it's the 200th anniversary of photography as a whole, CCR is celebrating 10 years on the air, and we've reached episode 200! So the gang digs into a few topics on this show! If you remember, back in Episode 100, we talked about the oldest cameras in our collections, so in this episode, we talk about the newest cameras in our toolkits. We will also talk about all the latest films that have emerged in the 21st century and the developers! CCR is ten years old this year, and to celebrate, we're hosting a Photowalk in Brewery Tour on 12 July starting at 11 am from the Great Lakes Brewpub at 11 Lower Jarvis in Toronto, Ontario. You can find more details on the event signup page on Photowalk.me!

The Deadcast cruises down the eastern seaboard, including stops in Hartford, Hampton, Philadelphia, and Landover, featuring touring tips, another police chase, & a visit to the White House.Guests: David Lemieux, Sam Cutler, Dennis Alpert, Tyler Roy-Hart, David Leopold, John Leopold, Rebecca Adams, Brian Schiff, Gary Lambert, Chris Goodspace, Winslow Colwell, Scott Jones, Chad EylerSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Conan is cracking us up, per usual. Sesame Street's future is in question. Is Nicole Kidman wearing a wig? Plus, the Diddy trial is continuing, and we aren't enjoying it. Kurt Cobain started in a CCR cover band, mosquitoes play favorites, and it's hard to imagine a time before the t-shirt. Would you sleep in a bed off the edge of a cliff?

Cine e parte a Sistemului care mizează pe Simion & Georgescu (DW) - Cum a fost sădită ura. Începuturi (HotNews) - Economia lui Nicușor Dan vs economia lui George Simion. Ce ne așteaptă după alegeri (Libertatea) Apără România! (Republica)România se află în poarta istoriei, în fața unui val, scrie jurnalistul Alex Livadaru, cofondator Republica.Dezinformare, extremism, izolaționism – toate acestea își fac loc în discursul public, uneori cu hainele seducătoare ale salvării. Iar românii au de ales: cedează sau apără. Se retrag sau votează.Pe 18 mai România are ocazia de a trimite la Palatul Cotroceni nu neapărat un președinte, cât un semnal cu valoare de simbol. Putem arăta că nu confundăm forța faptelor cu zgomotul. Că - în locul celor care promit cu voce tare nimicul ambalat în cuvinte vagi, dar aparent mari - alegem un om care a dovedit în tăcere: dublu medaliat cu aur la Olimpiada Internațională de Matematică, o minte formată în rigoarea științei și responsabilitatea meritului. Un om cu doctorat în Matematică făcut la Sorbona.Nu putem fi condamnați la frică și nici la imitarea celor care se închid între granițe mentale și fizice, intimidați de cei care țipă mai tare.Dar putem alege deschiderea, competența, discernământul. Putem arăta că patriotismul nu se strigă cu lozinci „noi contra lor”, ci se poate traduce prin „împreună, pentru mâine, pentru copiii noștri”.Cine e parte a Sistemului care mizează pe Simion & Georgescu (DW)Pentru a doua oară un judecător dă o decizie în favoarea „turului doi înapoi”, semnalând astfel că în Justiție există o grupare gata să încalce legea pentru a juca în favoarea lui Simion, notează Sabina Fati.Soluția judecătorului e ilegală, fiindcă hotărârile CCR nu sunt acte administrative şi, prin urmare, nu pot fi atacate în contencios administrativ, anulate sau suspendate.Până acum, pe rolul instanțelor din România au fost înregistrate peste 200 de cereri de desființare a deciziei Curții Constituționale privind anularea alegerilor prezidențiale, reamintește jurnalista DW.Hotărârile justiției sunt la suprafață, pot fi văzute, iar semnalele pe care le dau pot fi înțelese. Grupările din zona magistraților care sunt de partea cuplului Simion & Georgescu pot fi localizate și cartografiate, potrivit unor surse DW. În schimb, facțiunile din serviciile secrete sau din Armată și Poliție care-i împing în față pe acești radicali cu susținere la Moscova sunt mai greu de depistat. Totuși, înainte de 24 noiembrie 2024, ziua în care Călin Georgescu a câștigat primul tur al prezidențialelor fără să fi făcut măcar o zi de campanie electorală în spațiul real, nici SRI, nici SIE, nici vreo altă instituție care se ocupă cu siguranța națională nu a dat vreun avertisment și nu a vorbit despre vreun pericol care să vină dinspre extremismul cu rădăcini atât în legionarismul interbelic cât și în preferințele Moscovei. Practic, Rusia avea un candidat gata să ajungă la Cotroceni, dar serviciile românești nu și-au dat seama?Sunt oameni din Sistem (justiție, servicii, poliție, armată) care pot influența politicile și azimutul țării, uneori în bine, alteori în rău și nu de puține ori în propriile interese. În toate situațiile, puterea lor e dăunătoare pentru democrație și nimeni nu pare să poată să o oprească.  Cum a fost sădită ura. Începuturi (HotNews)Jurnalista Claudia Pîrvoiu a intrat pe grupurile de Telegram, a urmărit live-uri pe TikTok, un fel de dezbateri între compatrioții care se denumesc „patrioți”, „suveraniști” și „români adevărați”, organizate în fiecare noapte.  A descoperit discuții, dar și multă ură, care, pentru a fi menținută vie, este alimentată zilnic prin mesaje care îndeamnă la revoltă sau chiar violență.Această mișcare menită să aducă marea schimbare în România este foarte bine organizată și a fost creată în timp, avându-și rădăcinile dinainte de 2020. Semnale legate de nașterea unei forțe uriașe așa-zis suveraniste au existat, însă au fost ignorate de societatea civilă, politicieni, autorități, presă. Deși au existat și excepții, ziariști care au urmărit subiectul și l-au oferit oamenilor...Integral pe pagina HotNews.Economia lui Nicușor Dan vs economia lui George Simion. Ce ne așteaptă după alegeri (Libertatea)Analistul financiar Cristian Tudorescu a calculat care sunt scenariile economice care ne așteaptă după alegeri, în funcție de câștigătorul acestora.În cazul în care independentul Nicușor Dan va fi ales drept președinte al României cursul va rămâne aproximativ egal cu cel actual, dobânzile revin la nivelurile de acum câteva săptămâni, iar pentru echilibrarea bugetului va fi realizată o creștere mică de taxe, caz în care nivelul de trai va scădea cu 2-3% față de cel actual, a scris acesta pe Facebook. În schimb, în cazul în care va câștiga extremistul George Simion, atunci cursul se va deprecia în câteva săptămâni la 5,5 lei pentru un euro, dobânzile la care se împrumută statul vor deveni nesustenabile, fondurile europene de 13 miliarde de euro din Planul Național de Redresare și Reziliență (PNRR) vor rămâne blocate, iar în următoarele șase luni vor exista „creșteri semnficative de taxe”. În schimb, nivelul de trai ar urma să scadă cu 10-15%, mai arată Tudorescu, citat de Libertatea.

The Deadcast makes a beeline for the northeast, focusing on shows from legendary venues in the Manhattan and Boston areas included on the new Enjoying the Ride box, including ESP experiments, weed smuggling, free jazz titans, multiple police chases, and more.Guests: David Lemieux, Ron Rakow, Sam Cutler, Richie Pechner, Allan Arkush, Ned Lagin, Gary Lambert, Blair Jackson, Stanley Krippner, Rebecca Adams, Johnny Dwork, John Scher, Michael Simmons, Tyler Roy-Hart, Henry K, Howie Levine, Kenny Schiff, Debbie RondeauSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Episode 189: One Of The Main Musical Topics Of The 60s: Protest! May 6, 2025 One nonviolent way to show one's displeasure/disgust/disagreement is to protest. In a letter to the editor, written in a blog, by contacting your lawmakers, taking it to the streets and there are many other ways. Pete Seeger was known for his songs protesting mistreatment of workers and war itself, and over time there has been a great abundance of songs and actions of protest. Marvin Gaye, CCR, Nina Simone, Dylan, Lennon and many others wrote and performed their protest songs from What's Goin' on?, Blowin' in the Wind to Fortunate Son, Give Peace a chance and Strange Fruit. In the future you'll hear an episode of Tales Vinyl Tells dedicated to protest songs. Please send your ideas to me at TalesVinylTells@gmail.com and yours may well be included. And when you email me, please be sure to let me know who and where you are. I mention protest songs because we kick off with a real kicker from Quicksilver Messenger Service and include Petty, Joni, Cheech, Chong, Nick and more. Thanks for listening. I want to say thank you to all the financial supporters of Tales Vinyl Tells. Whether a small amount monthly or a very generous donation, each of you listeners is very appreciated and if you can and do give monthly, my deepest gratitude goes to you. If you're not a patron yet and want to know more about becoming a patron of this music program you can go Patron.podbean.com/talesvinyltellssupport. Thank you and rock on! And thanks for listening today.  My email is talesvinyltells@gmail.com.  If you want to hear a Tales Vinyl Tells when it streams live on RadioFreeNashville.org, we do that at 5 PM central time Wednesdays. The program can also be played and downloaded anytime at podbean.com, Apple podcasts, iHeart podcasts, Player FM podcasts and many other podcast places. And of course you can count on hearing the Tales on studiomillswellness.com/tales-vinyl-tells anytime.

Are you ever going to text me?This episode is running hands free.Jason, Jim, and Joseph recall their favorite TV series to revisit.Murky flush."Old Man" Joseph is complaining (about everything) again.Jason is unrestrained with the puns.I am a white man with hair in America.  I can do anything.Jim may have a case of "wired connectivity".Jason admits to being a real life "Hop On" the Bluth's stair car.One name... Gilligan.  Need Jim say anymore?Lovey Howell, the sexiest Honeybee.How long does it take Joseph to binge a seven-season series?  Hint: It is a ridiculously short amount of time.Which one of Jim's favorite shows is frequently played in the background during the recording of CCR shows.

Convention season is now in full swing. Next up - Comic Con Revolution (CCR)! Programming director David Nieves joins us to discuss what goes into putting on a pop culture convention. What were our first convention experiences? San Diego Comic Con was first for some, while others were relegated to a single banquet room at the local Sheraton Hotel (looking at you Richard). If you ever dreamed of working at a con, David gives tips on how you can make that happen.    David tells us about a NEW feature for this year's CCR. Attendees will have an opportunity to experience a special pop up with Trapped Escape Room. In The Henchmen's Heist, you and your crew are aspiring villains! You join Madame Graffiti's band of art thieves. The mission? To steal as many pieces of art as possible from the world-famous Lumina Museum at their annual Spectrum Gala.    Along with the many superstars and escape room, we will also be there with TWO of our Trivia party game shows. Sunday May 18th we will host our Pop Culture Trivia Challenge at 12pm. At 2:45 we will play our Star Wars Trivia Challenge Strikes Back!   Today in Star Wars History 5/2/2006   Revenge of the Sith wins top honors in two categories at the 32nd Saturn Awards. The film wins ‘Best Science Fiction Film' and John Williams wins for ‘Best Score.'   SPONSORS   Small World Vacations is an official sponsor of Skywalking Through Neverland. Contact them for a no obligation price quote at www.smallworldvacations.com. Tell them Skywalking Through Neverland sent you.   SUPPORT THE SHOW   Find out how you can become a part of the Skywalking Force and unlock bonus content.   CONTACT US   Instagram: http://instagram.com/skywalkingpod   Twitter: https://twitter.com/SkywalkingPod   Facebook: https://www.facebook.com/skywalkingthroughneverland   Send emails to share@skywalkingthroughneverland.com and follow us on Facebook.   If you dug this episode, click over to iTunes | Stitcher | YouTube and leave us a review!   Never Land on Alderaan!

Convention season is now in full swing. Next up - Comic Con Revolution (CCR)! Programming director David Nieves joins us to discuss what goes into putting on a pop culture convention. What were our first convention experiences? San Diego Comic Con was first for some, while others were relegated to a single banquet room at the local Sheraton Hotel (looking at you Richard). If you ever dreamed of working at a con, David gives tips on how you can make that happen.    David tells us about a NEW feature for this year's CCR. Attendees will have an opportunity to experience a special pop up with Trapped Escape Room. In The Henchmen's Heist, you and your crew are aspiring villains! You join Madame Graffiti's band of art thieves. The mission? To steal as many pieces of art as possible from the world-famous Lumina Museum at their annual Spectrum Gala.    Along with the many superstars and escape room, we will also be there with TWO of our Trivia party game shows. Sunday May 18th we will host our Pop Culture Trivia Challenge at 12pm. At 2:45 we will play our Star Wars Trivia Challenge Strikes Back!   Today in Star Wars History 5/2/2006   Revenge of the Sith wins top honors in two categories at the 32nd Saturn Awards. The film wins ‘Best Science Fiction Film' and John Williams wins for ‘Best Score.'   SPONSORS   Small World Vacations is an official sponsor of Skywalking Through Neverland. Contact them for a no obligation price quote at www.smallworldvacations.com. Tell them Skywalking Through Neverland sent you.   SUPPORT THE SHOW   Find out how you can become a part of the Skywalking Force and unlock bonus content.   CONTACT US   Instagram: http://instagram.com/skywalkingpod   Twitter: https://twitter.com/SkywalkingPod   Facebook: https://www.facebook.com/skywalkingthroughneverland   Send emails to share@skywalkingthroughneverland.com and follow us on Facebook.   If you dug this episode, click over to iTunes | Stitcher | YouTube and leave us a review!   Never Land on Alderaan!

What would you do if you got stuck in a cave? Cave diving is something that has fascinated - and terrified - us for a long time - and today we had the opportunity to get all our questions answered by acclaimed explorer and cave diver - Rannvá Jørmundsson. Rannvá has a background as a professional diving instructor, specialising in cold water. Rannvá is originally from the Faroe Islands, but currently lives in Cornwall, where she works for the diving equipment company Fourth Element. Rannva has been diving since 2008 and is an IDC Staff instructor and full cave CCR diver, and she is a member of the Explorers Club in New York.Rannvá told us all about her passion for diving, how she feels it's the best form of mediation and also how she uses her extensive training to handle the risks and dangers involved in cave exploration. Stay tuned to find out if she can convince us to take a dive...Follow @rannvaj on InstagramYou can read more about Rannvá's expedition to Mexico's Yucatan Peninsula here #PerpetualPlanetRannvá cofounded Nixie Expeditions - an organisation dedicated to Aquifer Exploration and Conservation. You can see more about their work on their Instagram - @nixie_expeditionsIf you'd like to get in touch, you can email us on shouldideletethatpod@gmail.com Follow us on Instagram:@shouldideletethat@em_clarkson@alexlight_ldnShould I Delete That is produced by Faye LawrenceStudio Manager: Dex RoyVideo Editor: Celia GomezSocial Media Manager: Emma-Kirsty FraserMusic: Alex Andrew Hosted on Acast. See acast.com/privacy for more information.

CCR caught up with some excited PHT patrons after the Padres won their first of a two-game set against the Giants 7-4 on the back of a Xander Bogaerts HR and 3 RBI performance.Want to get this show and tons of others early and ad-free? Plus access to our vaunted PHT Discord server and more? Become a patron at patreon.com/padreshottub

The Deadcast's tour of Enjoying the Ride trucks all the way to the East Bay, exploring beloved venues including the Greek Theater & Kaiser Auditorium, with tales of the Hog Farm's Skeleton Crew & vintage field recordings from Oakland Coliseum Arena's parking lot. Guests: David Lemieux, Ron Rakow, Kevin Schmevin, Mark Pinkus, Blair Jackson, Steve Silberman, Rebecca Adams, David Gans, Johnny Dwork, Tyler Roy-Hart, Steven Bernstein, Robert Nyberg, Chad KroegerSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This time, we're previewing Comic Con Revolution – Ontario with one of the creative forces behind it: Drew Seldin from Atomic Crush Events. It's shaping up to be a big eighth year for the CCR crew! Listen in and enjoy! New to the podcast? We recommend starting with Episode 879, our 10th anniversary retrospective, which offers great context for the Parks and Cons universe. A huge THANK YOU to our amazing Patreon supporters—your support keeps the show running! Special shout-outs to our incredible Omega Level, Super Soldier Powerhouse, Otherworldly Powerhouse, and Mutant Powerhouse tier supporters: Renee A., Brett A., Johanna A., Angela B., Jennifer B., Michael B., Steve C., Drew D., Kerry D., Rochelle D., Ted D., Mike E., Tim F., Tina F., Yvette G., Jonathan G., Clarisa H., Hailey K., Jason M., Susan O., Tom P., Joshua R., Albert R., Sandra S., Manuel S., Hendel T., Alyssa W., Adam W., Jamie W., Mark W., John W., and our anonymous donor. Want to join the Parks and Cons Crew? Become a supporter on Patreon: https://www.patreon.com/ParksAndCons Prefer a one-time contribution? Learn how you can donate here.

Here comes the second of two parts featuring some of rock's most celebrated artists who had a penchant for the rich traditions of the corner stone of rock and roll music that leans to the country, including Eric Clapton and J.J. Cale, U2, more Neil Young, more Rolling Stones, Allman Bros, CCR, John Hiatt, Brinsley Schwarz, Nick Lowe, The Who, Robert Plant and Alison Krauss, Pink Floyd plus a Canadian tribute to them, PLUS a ton of bonus content (making this the most in depth radio show podcast episode yet, with yet another dozen plus rock bands, some of whom are sure to surprise, who found themselves in the country too. I'll give you a hint: Metallica country?!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Various names, including Modern Grain, Delta Grain, or T-Grain, are known for these films. These are the newest style of black and white film emulsions that offer fine grain, added sharpness, and a distinctly different structure than traditional cubic-grained film. In this episode, the team sits down to discuss films from Ilford Delta, Kodak TMax, Fomapan 200, and the Fujifilm Neopan line, as well as the various and assorted developers designed to maximise the potential of these modern films. But we also dig into developers like Kodak TMax Developer, Ilford DD-X, and Crawley's FX-37! There is also a Canadian Federal Election taking place on April 28. We at CCR encourage all eligible Canadians to get out and vote! You can visit the Elections Canada website to find out if you're eligible, register to vote, and where to cast your ballot! And if you haven't already, make sure to cast your ballot on Election Day, April 28, 2025. CCR is ten years old this year, and to celebrate, we're hosting a Photowalk on Brewery Tour on July 12, starting at 11 am from the Great Lakes Brewpub, located at 11 Lower Jarvis in Toronto, Ontario. You can find more details on the event signup page on Photowalk.me!    

In this episode of Citizens Climate Radio, Elise Silvestri explores how art can strengthen climate advocacy with Carrie Ziegler, an interdisciplinary Artist, Speaker, and Community Engagement Expert. Carrie talks about her process for creating and executing the Chrysalis Project: Transforming Together, an art and climate policy project that enacted powerful change over Zoom during the COVID-19 pandemic. One of the participating students, Brisa Sabel, shares her experience of the successful campaign and the  joy and inspiration it gave her.  Peterson Toscano has a surprisingly good news story: like our responses to climate change, the format of CCR is adapting! [insert finalized details here] Listen to Carrie Ziegler discuss the power of art storytelling in making meaningful, local climate policy. Guest Bio: Carrie Ziegler Carrie Ziegler harnesses the collective power of art to drive social and environmental transformation. Through her Art in Action initiatives, she collaborates with diverse entities—local governments, organizations, schools, and universities—to create multi-dimensional works that blend participant creativity with pressing societal issues. These projects inspire active engagement, bringing communities together to create lasting change. Along with the Chrysalis Project, Carrie also led the Plastic Whale Project, where students created a life-sized whale out of plastic bags. The whale played a pivotal role in successfully passing a ban on single-use plastic bags in Olympia, Lacey, Tumwater, and Thurston County, Washington.   Based in Olympia, Washington, Carrie is recognized internationally, bringing her impactful vision to global forums, including Aotearoa (New Zealand), Ghana, France, Mexico, and Canada. She empowers Artists and Change Makers to maximize their societal impact through art, inspiring a broader movement of change driven by creativity. Complementing her hands-on work, Carrie is penning her inaugural book, Eclosion: An Artist's Path to Power and Peace. In this work, she intertwines her memoir with a practical guide for unleashing personal and collective potential, offering a blueprint for transformative change through art—a light for a world in desperate need of inspiration. Check out her work on her Instagram, @carriezieglerart.

Elise Silvestri explores how art can strengthen climate advocacy with Carrie Ziegler, an interdisciplinary Artist, Speaker, and Community Engagement Expert. Carrie talks about her process for creating and executing the Chrysalis Project: Transforming Together, an art and climate policy project that enacted powerful change over Zoom during the COVID-19 pandemic. One of the participating students, Brisa Sabel, shares her experience of the successful campaign and the joy and inspiration it gave her. Peterson Toscano has a surprisingly good news story: like our responses to climate change, the format of CCR is adapting! [insert finalized details here] Listen to Carrie Ziegler discuss the power of art storytelling in making meaningful, local climate policy. Carrie Ziegler harnesses the collective power of art to drive social and environmental transformation. Through her Art in Action initiatives, she collaborates with diverse entities—local governments, organizations, schools, and universities—to create multi-dimensional works that blend participant creativity with pressing societal issues. These projects inspire active engagement, bringing communities together to create lasting change. Along with the Chrysalis Project, Carrie also led the Plastic Whale Project, where students created a life-sized whale out of plastic bags. The whale played a pivotal role in successfully passing a ban on single-use plastic bags in Olympia, Lacey, Tumwater, and Thurston County, Washington. Based in Olympia, Washington, Carrie is recognized internationally, bringing her impactful vision to global forums, including Aotearoa (New Zealand), Ghana, France, Mexico, and Canada. She empowers Artists and Change Makers to maximize their societal impact through art, inspiring a broader movement of change driven by creativity. Complementing her hands-on work, Carrie is penning her inaugural book, Eclosion: An Artist's Path to Power and Peace. In this work, she intertwines her memoir with a practical guide for unleashing personal and collective potential, offering a blueprint for transformative change through art—a light for a world in desperate need of inspiration. Check out her work on her Instagram, @carriezieglerart.

It's postban modern RCQ season! We're playing all sorts of bad decks this time around, from Hardened Broodscale to Coretapper Control. Well, Lee is playing those decks while CCR goes long on Prowess. Come check out the format with us! Thanks as always to Wave Sunray for our music! If you'd like to support the podcast, check out our patreon at patreon.com/mtggrindcast. Subscribers get swag and bonus content! And whether you subscribe or not, you're invited to join our discord, where we're building a community of friendly people all looking to improve at the game we love. Check it out here: https://discord.gg/Uq8x2RHYRU

In this episode, join us for CCR's most controversial Episode Ever!Follow:Zac Loughman @https://www.instagram.com/dr_crawdad/On FB https://www.facebook.com/profile.php?id=100011423011423Clint Bartley @IG: MetazoticsLLC FB: MetazoticsWebsite: metazotics.comPatreon:https://www.patreon.com/c/ColubridandColubroidRadio/Discord:http://discord.gg/ccradioExo-terrahttps://exo-terra.comhttps://linktr.ee/exoterrausaMPR NetworkFB: https://www.facebook.com/MoreliaPythonRadioIG: https://www.instagram.com/mpr_network/YouTube: https://www.youtube.com/channel/UCtrEaKcyN8KvC3pqaiYc0RQSwag store: https://teespring.com/stores/mprnetwork ★ Support this podcast on Patreon ★

Can a glass of pomegranate juice really help slow the growth of prostate cancer? In this episode of The Moss Report, Ben Moss and Dr. Ralph W. Moss take a deep dive into the clinical research on pomegranate and cancer—especially prostate cancer. They explore landmark studies from Johns Hopkins and UCLA, uncover the political backstory behind the POMx extract, and offer practical guidance for integrating pomegranate into a cancer-fighting or preventative diet. Dr. Moss also shares his personal use of pomegranate powder, discusses antioxidant synergy, and introduces options that reduce sugar intake without sacrificing benefits. A compelling look at how traditional foods meet cutting-edge science. “Fill up that self-help space with scientifically documented ways to reduce your cancer risk.” – Dr. Ralph W. Moss

ReferencesCell Mol Biol (OMICS). 2015 Dec.31;61(2):121Circulation 2018. Volume 138, Issue 22, 27 November :2513-2526.Cancers (Basel). 2023 Jan 20;15(3):657Winwood&Capaldi.1968 "Dear Mr Fantasy" livehttps://open.spotify.com/track/01Fj94JZRJN6RGRVsjO0nt?si=dc13fca60f424b2eFogerty, J. 1969."Fortunate Son" CCR.https://open.spotify.com/track/4BP3uh0hFLFRb5cjsgLqDh?si=9d1be1c2b64e47eeSchmelzer, J. 1664. Violin Sonatas.Romanesca.https://open.spotify.com/album/1XfJrmtHCHOs7X8EdpEadj?si=fKgdDGU5S1Cy2o74G-f96A

The Deadcast begins our virtual tour of the new Enjoying the Ride box, visiting the cradle of the Dead in Palo Alto/Menlo Park (with a detour to visit the Warlocks' earliest shows) before heading to San Francisco with stops at the Fillmore West and Winterland.Guests: Connie Bonner Mosley, Ron Rakow, Ned Lagin, Ron Pietrowski, Tyler Roy-Hart, Les Earnest, Doug Oade, Eric Schwartz, Blair Jackson, Michael Parrish, Dominic Stefano, David LemieuxSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

CCR hop on with our patrons after a rollercoaster series in West Sacramento that see the Padres returning to San Diego with the best record in baseball.Want to get this show and tons of others early and ad-free? Plus access to our vaunted PHT Discord server and more? Become a patron at patreon.com/padreshottub

From McCartney, The Stones, Creedence Clearwater Revival and Bob Dylan, to Live Aid, farewell tours, tribute acts and Cherry Garcia ice cream. This book by David Hepworth, documents how and why rockers have made it this long, and looks at the pivotal moments that pushed their careers, whether they liked it or not, into the future. *Want to win a free copy of Mike Campbell's memoir Heartbreaker?  It's easy, just send me an email to sign up. You can find a link to my email address below. *Reminder this is for US citizens only**Want to stay on top of the world of Rock N Roll Book and Documentaries? That's also easy. Sign up for the Monthly BLAST!! the newsletter that comes out on the last Friday of the month that features book buzz and doc news, recently released titles, top 5 lists, and more. Just shoot me over an email at the address below and say Big Rick, send me that Blast!!Support the showemail Big Rick at:info@rocktalkstudio.com

For the 50th anniversary reissue of Tiger Rose, we explore the lost story of Robert Hunter & Jerry Garcia's only full-length studio collaboration, the Dead lyricist's 2nd solo album, produced by Garcia & performed by an all-star cast including Garcia, Mickey Hart, & Donna Jean Godchaux.Guests: Kathy Veda Vaughan Bogert, Mickey Hart, Barry Melton, Ron Rakow, Howie LevineSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In the 2nd part of the Deadcast's Phil Lesh tribute, we get deep into his singular bass playing with Phil's son & bandmate Grahame, Phish's Mike Gordon, & musicologist Rob Collier, while touring Phil's high adventures with Ned Lagin, radio co-host Gary Lambert, & other friends.Guests: Grahame Lesh, Mike Gordon, Ned Lagin, David Crosby, David Lemieux, Gary Lambert, Rob CollierSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The Deadcast begins its 11th season with a celebration of the Grateful Dead's Phil Lesh, drawing on archival interviews to explore his unusual trajectory from jazz trumpet to avant-garde composition to rock and roll bass, and welcoming special guest Mike Gordon of Phish.Guests: Mike Gordon, Oteil Burbridge, Sam Cutler, David Lemieux, Gary LambertSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.